A Phase 1b Study of the Multi-Kinase Inhibitor Regorafenib in Combination With the BCL-2 Inhibitor Venetoclax Plus Azacitidine in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Latest Information Update: 30 May 2025
At a glance
- Drugs Azacitidine (Primary) ; Regorafenib (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
Most Recent Events
- 26 May 2025 Status changed to suspended.
- 26 May 2025 Planned End Date changed from 17 Feb 2027 to 6 Sep 2030.
- 26 May 2025 Planned primary completion date changed from 17 Feb 2027 to 6 Sep 2030.